Cognito Therapeutics is a digital therapeutics startup that specializes in discovering and developing treatments for neurodegenerative diseases, including Alzheimer’s disease (AD), using its proprietary neuromodulation platform.
Founded in 2016, Massachusetts-based Cognito Therapeutics uses gamma frequency neuromodulation therapy—involving auditory and visual stimuli to evoke patient-specific brain activity—to treat AD. The company received a Breakthrough Device Designation from the US Food & Drug Administration (FDA) in January 2021.
In March 2021, the company announced that its novel disease-modifying treatment for AD has shown positive results from a Phase II clinical study. The company plans to go ahead with a large-scale pivotal clinical study required in the FDA approval process. The company announced that its novel disease-modifying treatment for AD has shown positive results from a Phase II clinical study. The company planned to go ahead with a large-scale pivotal clinical study in 2022.
Key customers and partnerships
The company partnered with Aetion, a Real-World Evidence (RWE) technology and analytics provider, to create a predictive model to identify individuals at risk of AD and mild cognitive impairment so that they could benefit from early treatment. This model would also help to speed up the clinical development of Cognito’s late-stage clinical program.
Funding and financials
In March 2023, the company raised USD 73 million in a Series B funding round led by FoundersX Ventures, along with participation from other venture capital firms and the Alzheimer’s Drug Discovery Foundation. The funds were set aside to expedite the company’s Phase III clinical study of its non-invasive neuromodulation device for the treatment of Alzheimer’s disease. Post-funding, Dr. Rick Kuntz, the founder and managing partner at FoundersX, joined Cognito’s board of directors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.